

# Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up

NCT07209852

---

**Status** RECRUITING  
**Sponsor** Boston Scientific Corporation  
**Enrollment** 140 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Subjects intended to undergo initial (de novo) pacing system implant using the INGEVITY+ lead in the left bundle branch area (LBBA) and a Boston Scientific single or dual- chamber pacemaker (Note: no prior attempted pacing system components);
- Subjects who are indicated for and will receive a Boston Scientific pacemaker system (including the single or dual chamber pacemaker and an INGEVITY+ lead in the LBBA location) for one of the following medical conditions:
- Symptomatic paroxysmal or permanent second- or third-degree AV block,
- Symptomatic bilateral bundle branch block,
- Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial \[SA\] block),
- ... and 9 more (see full listing online)

### Exclusion (11)

- Subjects meeting guideline indications for cardiac resynchronization therapy (CRT) in the absence of a bradycardia indication;
- Subjects with a known or suspected sensitivity to dexamethasone acetate (DXA);
- Subjects with a Mechanical Tricuspid Valve;
- Subjects requiring hemodialysis or peritoneal dialysis;
- Subject has or has had implanted any pacemaker, ICD system, including subcutaneous, transvenous or leadless systems (Note: except for temporary pacing wire at time of enrollment) or CRT system;
- ... and 6 more (see full listing online)

## Locations (13 total)

---

St. Jan-Hospital, Bruges, Belgium  
Clinique Saint-Pierre Ottignies-Hospital, Brussels, Belgium  
CHRU de Lille, Lille, France  
... and 10 more locations